RAPP
USDRapport Therapeutics Inc. Common Stock
实时价格
价格图表
关键指标
市场指标
开盘价
$26.440
最高价
$26.440
最低价
$24.600
成交量
0.24M
公司基本面
市值
1.2B
所属行业
生物技术
国家/地区
United States
交易统计
平均成交量
0.80M
交易所
NGM
货币
USD
52周价格范围
相关新闻
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Truist Securities Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $44
Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics with a Buy rating and announces Price Target of $44.
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Pricing of Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Proposed Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics with a Buy and raises the price target from $31 to $34.
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for
